HKI 357

Modify Date: 2025-08-21 21:07:41

HKI 357 Structure
HKI 357 structure
Common Name HKI 357
CAS Number 848133-17-5 Molecular Weight 574.04500
Density N/A Boiling Point N/A
Molecular Formula C31H29ClFN5O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of HKI 357


HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation[1].

 Names

Name (E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
Synonym More Synonyms

 HKI 357 Biological Activity

Description HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation[1].
Related Catalog
Target

EGFR:34 nM (IC50)

ErbB2:33 nM (IC50)

In Vitro HKI-357 (0.01-10 μM) is effective in suppressing ligand-induced EGFR autophosphorylation and its downstream signaling, as determined by AKT and MAPK phosphorylation in NCI-H1975 cells[1]. HKI-357 also is effective in suppressing EGFR autophosphorylation (measured at residue Y1068), and AKT and MAPK phosphorylation in parental NCI-H1650 cells harboring the delE746-A750 EGFR mutation[1]. Western Blot Analysis[1] Cell Line: NCI-H1975 bronchoalveolar cell line Concentration: 0.01, 0.01, 0.1, 1 and 10 μM Incubation Time: Result: Suppressed ligand-induced EGFR autophosphorylation and its downstream signaling AKT and MAPK phosphorylation.
References

[1]. Kwak EL, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70.

 Chemical & Physical Properties

Molecular Formula C31H29ClFN5O3
Molecular Weight 574.04500
Exact Mass 573.19400
PSA 106.23000
LogP 6.74798

 Synthetic Route

~78%

HKI 357 Structure

HKI 357

CAS#:848133-17-5

Literature: Wyeth Patent: US2005/59678 A1, 2005 ; Location in patent: Page 4-5 ; US 20050059678 A1

~81%

HKI 357 Structure

HKI 357

CAS#:848133-17-5

Literature: WYETH Patent: WO2005/34955 A1, 2005 ; Location in patent: Page/Page column 13-14 ; WO 2005/034955 A1

~%

HKI 357 Structure

HKI 357

CAS#:848133-17-5

Literature: Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan Journal of Medicinal Chemistry, 2005 , vol. 48, # 4 p. 1107 - 1131

~%

HKI 357 Structure

HKI 357

CAS#:848133-17-5

Literature: Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan Journal of Medicinal Chemistry, 2005 , vol. 48, # 4 p. 1107 - 1131

~%

HKI 357 Structure

HKI 357

CAS#:848133-17-5

Literature: Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan Journal of Medicinal Chemistry, 2005 , vol. 48, # 4 p. 1107 - 1131

 Synonyms

HKI 357
L-733,060 hydrochloride
UNII-39R3638KZ6
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here



Get all suppliers and price by the below link:

HKI 357 suppliers


Price: ¥9500/10 mg

Reference only. check more HKI 357 price

Related Compounds: More...
(Z)-but-2-enedioic acid,(E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
915942-25-5
Neratinib (HKI-272)
698387-09-6
Fluorescent Brightener 357
83512-97-4
Acid Brown 357
61814-63-9
sodium bis[2-[[1-(2-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]benzoato(2-)]chromate(1-)
71361-25-6
[N,N',N'',N'''-tetrakis[2-(hexadecyloxy)phenyl]-29H,31H-phthalocyaninetetrasulphonamidato(2-)-N29,N30,N31,N32]copper
79953-86-9
Fluorescent Brightener 357
41098-56-0
Carbamic acid, (4-methyl-1,3-phenylene)bis-, bis[2-[ethyl[(perfluoro-C4-8-alkyl)sulfonyl]amino]ethyl] ester
68081-83-4
Mucin
84195-52-8
2-[[1-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinylidene]methyl]-5-methoxy-1-methyl-1h-indole-3-carboxylic acid
122946-89-8
2-[[1-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinylidene]methyl]-1-methyl-1h-indole-3-carboxylic acid
122946-90-1
4-methyl-N-(4-oxo-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)benzamide
919858-15-4
2,4-dimethoxy-N-(4-oxo-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)benzamide
919842-02-7
(E)-3-(3,4-dimethoxyphenyl)-N-(4-oxo-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)acrylamide
946227-47-0
N-(4-oxo-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)-2,2-diphenylacetamide
919842-10-7
N-(4-oxo-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)-3,3-diphenylpropanamide
919858-27-8
N-(1-(3-chlorophenyl)-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)acetamide
919842-46-9
N-(1-(3-chlorophenyl)-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)propionamide
919858-63-2
2-chloro-N-(1-(3-chlorophenyl)-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)acetamide
919858-90-5